The updated label with additional data reinforces the safety and efficacy profile of Biktarvy to treat pregnant people with HIV-1 with suppressed viral loads, the company said.
Pre-exposure prophylaxis, or PrEP, has revolutionized HIV prevention. New technologies, including injectables, wider availability and the reduction of stigma are the next frontier.
Patients with HIV who were resistant to treatment with lenacapavir (Sunlenca; Gilead Sciences Inc) were found to have inadequate adherence to optimized background regimen or did not have a fully active antiretroviral.
Gilead shares results from HIV trial for lenacapavir pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.